Sorafenib [SOR2]

The treatment of differentiated thyroid cancer after radioactive iodine where the following criteria are met:

  1. This application is made by and the first cycle of systemic anti-cancer therapy with sorafenib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. This patient has a confirmed histological diagnosis of differentiated thyroid carcinoma (papillary or follicular or Hurtle cell type) 3.The patient has either metastatic disease or inoperable locally advanced disease
  3. The disease is refractory to radioactive iodine
  4. The disease is progressive and is either symptomatic or imminently likely to become symptomatic
  5. The patient is treatment naïve to both lenvatinib and sorafenib unless the patient has had to discontinue lenvatinib within 3 months of starting lenvatinib because of toxicity (ie there is lenvatinib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on lenvatinib. Note: Sequential use of sorafenib and then lenvatinib is only funded if the patient has to discontinue sorafenib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on sorafenib. The use of sorafenib after disease progression on or after lenvatinib is not funded and vice versa.
  6. The patient has an ECOG performance status of 0 or 1 or 2.
  7. Sorafenib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment.
  8. A formal medical review as to whether treatment with sorafenib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment
  9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)
  10. Sorafenib is to be otherwise used as set out in its Summary of Product Characteristics

[NHS funded]{.badge .rounded-pill .bg-success} From: 06 November 2018

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA535 (08 August 2018)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.